Newly released results from LEO Pharma’s phase 3b ADHAND trial have supported the efficacy and safety of Adbry (tralokinumab) for adults with atopic dermatitis (AD) involving the hands.

Top-line results from week 32 of the trial reflect the positive results seen at week 16. By week 16, 40% of patients receiving tralokinumab had achieved an Investigator’s Global Assessment for Atopic Hand Eczema (IGA-AHE) score of 0/1, meaning clear or almost clear skin on the hands. 

Similarly, 47.3% of treated patients showed a clinically meaningful reduction in itch, and 45.3% showed a clinically meaningful reduction in pain.

Throughout the 32-week trial period, tralokinumab showed a consistently favourable safety profile, with rates of adverse events equivalent between tralokinumab and placebo groups. The trial identified no new safety signals associated with the drug.

Teodora Festini, who presented the study at the International Symposium on Atopic Dermatitis Congress 2025 in Melbourne, said: “The detailed 16-week results and now these high-level findings from week 32 underscore LEO Pharma's commitment to making a difference for patients with atopic dermatitis.”

AD is a chronic inflammatory condition characterised by discoloured, itchy and inflamed skin. Its presence on the hands can cause physical discomfort, issues with everyday tasks and social isolation due to embarrassment. Additionally, AD on the hands is hard to treat, because of the sensitivity of hand skin to external AD triggers.

Tralokinumab is a monoclonal antibody that targets and neutralises IL-13, a cytokine associated with inflammation.

Christophe Bourdon, CEO of LEO Pharma, said: “Seeing such positive outcomes in these visible, high burden areas gives us a brighter outlook on what we can achieve for those living with this challenging condition.”